Home・Список акций・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Открыт

СекторЗдравоохранение

66.18 1.69

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

63.88

Макс.

66.3

Ключевые показатели
By Trading Economics
Доход	1.6B 2.7B
Продажи	-1B 11B
P/E Средняя по отрасли	17.524 64.641
Прибыль на акцию	1.58
Дивидендная доходность	4.03
Рентабельность продаж	23.309
Сотрудники	32,500
EBITDA	1.5B 3.7B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+0.57% upside

Дивиденды
By Acuity
Дивидендная доходность Средняя по отрасли	4.03% 2.31%
Следующий отчет о доходах	29 окт. 2026 г.
Следующая эксдивидендная дата	2 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	9.8B 128B
Предыдущая цена открытия	64.49
Предыдущая цена закрытия	66.18

Новостные настроения

By Acuity

48%

52%

146 / 340 Рейтинг в Healthcare

Bristol-Myers Squibb Co. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 июл. 2026 г., 19:16 UTC

News

Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 июл. 2026 г., 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 июл. 2026 г., 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 июл. 2026 г., 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27 июл. 2026 г., 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24 июл. 2026 г., 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23 июл. 2026 г., 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22 июл. 2026 г., 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21 июл. 2026 г., 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20 июл. 2026 г., 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Сравнение c конкурентами

Изменение цены

Bristol-Myers Squibb Co. Прогноз

Целевая цена

By TipRanks

0.57% рост

Прогноз на 12 месяцев

Средняя 65.84 USD 0.57%

Максимум 80 USD

Минимум 40 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для Bristol-Myers Squibb Co. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

20 ratings

Покупка

Удержание

Продажа

Основано на мнении 20 аналитиков, присваивавших рейтинги акциям Bristol-Myers Squibb Co. – Данные за последние 3 месяца.

Настроения

By Acuity

146 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.